Core Viewpoint - The AI Fund Agricultural Bank Healthcare Stock (000913) reported a profit of 142 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1565 yuan, and a net asset value growth rate of 10.67% during the reporting period [2] Fund Performance - As of the end of Q2 2025, the fund's scale was 1.441 billion yuan [13] - The fund's unit net value as of July 17 was 1.875 yuan [2] - The fund's one-year cumulative net value growth rate was 38.71%, ranking 24 out of 53 comparable funds [2] - The fund's three-month cumulative net value growth rate was 26.79%, ranking 28 out of 54 comparable funds [2] - The fund's six-month cumulative net value growth rate was 42.95%, ranking 22 out of 54 comparable funds [2] - The fund's three-year cumulative net value growth rate was -9.44%, ranking 24 out of 46 comparable funds [2] Risk Metrics - The fund's three-year Sharpe ratio was -0.143, ranking 33 out of 46 comparable funds [7] - The maximum drawdown over the past three years was 40.52%, ranking 23 out of 46 comparable funds [8] - The highest single-quarter maximum drawdown occurred in Q1 2021, at 28.61% [8] Investment Strategy - The fund manager defined investment keywords for 2025 as innovation, medical AI, self-control, and state-owned enterprise reform [2] - The average stock position over the past three years was 90.34%, compared to the industry average of 88.16% [11] - The fund reached its highest stock position of 93.72% at the end of Q3 2020 and its lowest of 84.43% at the end of Q3 2024 [11] Top Holdings - As of the end of Q2 2025, the fund's top ten holdings included companies such as Heng Rui Medicine, Zejing Pharmaceutical, and Xinlitai [15]

Group 1 - The company held its 18th meeting of the second Supervisory Board on July 15, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2] - The Supervisory Board decided to abolish the Supervisory Board and transfer its powers to the Audit Committee of the Board of Directors, in accordance with the new Company Law and the revised Guidelines for Listed Companies [1][2] - The company plans to modify its business scope and amend relevant provisions in its Articles of Association to reflect these changes [1] Group 2 - The company proposed to reappoint Zhonghui Certified Public Accountants as the financial report auditor and internal control auditor for the fiscal year 2025, with audit fees to be negotiated based on market principles [2] - The resolution regarding the reappointment of the auditing firm received unanimous approval from all supervisors and will be submitted to the shareholders' meeting for further consideration [2]

Core Viewpoint - The company establishes an investor relations management system to enhance communication with investors, protect their rights, and improve corporate governance and overall value [2][3][4]. Group 1: Principles of Investor Relations Management - The investor relations management should adhere to compliance, equality, proactivity, and honesty principles [4][7]. - The company must treat all investors equally, especially facilitating participation for small and medium investors [4]. - The management activities should be proactive, listening to investor feedback and responding to their needs [4]. Group 2: Communication Channels and Methods - The company should utilize multiple channels for investor relations, including the official website, new media platforms, and direct communication methods like phone and email [5][6]. - It is essential to establish a dedicated investor relations section on the company website to address inquiries and complaints [6][12]. - The company should organize events such as roadshows and analyst meetings to communicate its situation and gather feedback [6][7]. Group 3: Responsibilities and Management Structure - The board secretary is responsible for coordinating investor relations activities, supported by the securities department for daily management [9][24]. - The company must ensure that all communications are accurate, complete, and comply with legal disclosure obligations [15][26]. - Staff involved in investor relations should possess relevant skills and knowledge, including understanding corporate governance and financial regulations [10][12]. Group 4: Handling Investor Inquiries and Complaints - The company is responsible for addressing investor inquiries and complaints promptly and effectively [21][22]. - It should actively support investor protection organizations and facilitate the exercise of shareholder rights [20][22]. - The company must maintain a clear distinction between promotional materials and independent media reports [9]. Group 5: Documentation and Record-Keeping - The company should maintain comprehensive records of investor relations activities, including participant details and communication content [28]. - All activities should be documented and made available on the designated investor relations platform [28]. Group 6: Implementation and Compliance - The investor relations management system will take effect upon approval by the board and will be revised as necessary [30]. - Any matters not covered by this system will be governed by relevant regulations from the China Securities Regulatory Commission and the Shanghai Stock Exchange [29].

Core Viewpoint - The company establishes a long-term mechanism to prevent the controlling shareholder and related parties from occupying company funds, ensuring the safety of company assets and compliance with relevant laws and regulations [1][2][3] Group 1: Mechanism for Prevention - The company aims to prevent both operational and non-operational fund occupation by the controlling shareholder and related parties [1][2] - The company must maintain independence in personnel, assets, and finances from the controlling shareholder and related parties [2][3] - The board of directors and internal institutions should operate independently and manage the company without interference from the controlling shareholder [2][3] Group 2: Fund Management Restrictions - The company is prohibited from providing funds to the controlling shareholder and related parties for non-operational expenses, including wages, benefits, and advertising [2][3] - Strict limitations are placed on the company regarding the provision of guarantees and loans to the controlling shareholder and related parties [3][4] - Any funds occupied by the controlling shareholder must be repaid in cash, with strict controls on non-cash asset repayments [5][6] Group 3: Responsibilities and Oversight - The chairman of the board is the primary responsible person for preventing fund occupation, with specific roles assigned to the board secretary and financial officer [3][4] - Regular inspections by the finance and audit departments are mandated to monitor transactions with the controlling shareholder and related parties [4][5] - Legal actions may be taken against the controlling shareholder if they occupy company funds or assets, including reporting to regulatory authorities [5][6] Group 4: Compliance and Amendments - The company must adhere to national laws and regulations, and any amendments to this system must be reported and approved by the shareholders [7] - The board of directors is responsible for interpreting this system and ensuring compliance with relevant laws [7]

上海毕得医药科技股份有限公司 董事会议事规则 第一章 总 则 第一条 为明确公司董事会的职责权限，规范公司董事会的议事方式和决策 程序，促使公司董事和董事会有效地履行职责，提高公司董事会规范运作和科学 决策水平，根据《中华人民共和国公司法》 第三条 公司董事会的组成由公司章程作出规定。 第四条 董事会在《公司法》和公司章程规定的范围内依法行使职权。 第五条 公司董事为自然人，有下列情形之一的，不能担任公司的董事： （以下简称"《公司法》"）、 《中华人民 共和国证券法》、《上市公司章程指引》、《上海证券交易所科创板股票上市规则》 （以下简称"《股票上市规则》"）、《上市公司治理准则》及《上海毕得医药科技 股份有限公司章程》（以下简称"公司章程"）等有关规定，制定本规则。 第二章 董事会的组成和职权 第二条 公司依法设立董事会。 （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序， 被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾 5 年，被宣告缓刑的， 自缓刑考验期满之日起未逾 2 年； （三）担任破产清算的公司、企业的董事或者厂长、经理，对该公司 ...

董事会议事规则 第一章 总 则 第一条 为明确公司董事会的职责权限，规范公司董事会的议事方式和决策 程序，促使公司董事和董事会有效地履行职责，提高公司董事会规范运作和科学 决策水平，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》、《上市公司章程指引》、《上海证券交易所科创板股票上市规则》 （以下简称"《股票上市规则》"）、《上市公司治理准则》及《上海毕得医药科技 股份有限公司章程》（以下简称"公司章程"）等有关规定，制定本规则。 第二章 董事会的组成和职权 第二条 公司依法设立董事会。 上海毕得医药科技股份有限公司 第三条 公司董事会的组成由公司章程作出规定。 第四条 董事会在《公司法》和公司章程规定的范围内依法行使职权。 第五条 公司董事为自然人，有下列情形之一的，不能担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （八）法律、行政法规或部门规章规定的其他情形。 董事候选人存在以下情形的，公司应当披露候选人具体情形、拟聘请该候选 人的原因以及是否影响公司规范运作： （一）最近 36 个月内受到中国证监会行政处罚； （二）因贪污、贿赂、侵占财产、挪用财产或者破 ...

上海毕得医药科技股份有限公司 股东会议事规则 第一章 总 则 第一条 为规范公司行为，保证股东依法行使职权，根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》、《上市公司章程指 引》、《上海证券交易所科创板股票上市规则》、《上市公司治理准则》、《上市公司 股东会规则》以及其他法律、行政法规和《上海毕得医药科技股份有限公司章程》 （以下简称"公司章程"）的规定，制定本规则。 第二条 公司应当严格按照法律、行政法规、公司章程的规定召开股东会， 保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第二章 股东会的一般规定 第四条 公司股东会由全体股东组成。股东会是公司的权力机构，在《公司 法》和公司章程规定的范围内依法行使职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 并应于上一会计年度完结后的 6 个月内举行。 临时股东会不定期召开，出现《公司法》、公司章程及本规则第九条规定的 应当召开临时股东会的情形 ...

上海毕得医药科技股份有限公司 内幕信息知情人登记管理制度 第一章 总 则 第一条 为了规范上海毕得医药科技股份有限公司（以下简称"公司"）的内 幕信息管理，加强内幕信息保密工作，维护信息披露公平原则，保护投资者合 法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司信息披露管理办法》（以 下简称"《管理办法》"）、《上市公司监管指引第 5 号——上市公司内幕信息知 情人登记管理制度》等法律、法规、规范性文件以及《上海毕得医药科技股份 有限公司章程》(以下简称"《公司章程》")的有关规定，结合公司的实际情况， 制定本制度。 第二条 公司董事会应当按照本制度以及证券交易所相关规则要求及时登记 和报送内幕信息知情人档案，并保证内幕信息知情人档案真实、准确和完整， 董事长为主要责任人。董事会秘书负责办理公司内幕信息知情人的登记入档和 报送事宜。董事长与董事会秘书应当对内幕信息知情人档案的真实、准确和完 整签署书面确认意见。 第三条 未经董事会批准，公司任何部门和个人不得向外界泄露、报道、传 送有关涉及公司内幕信息及信息披露的内容。对外报道、传 ...

上海毕得医药科技股份有限公司 关联交易管理制度 第一章 总 则 第一条 上海毕得医药科技股份有限公司（以下简称"公司"）为保证与各关联人发 生之关联交易的公允性、合理性，完善公司法人治理结构，促进公司规范运作，更好地 保护全体股东特别是中小股东的合法权益，根据《中华人民共和国公司法》《上市公司 治理准则》《上海证券交易所科创板股票上市规则》等法律、法规、规范性文件及《上 海毕得医药科技股份有限公司章程》（以下简称"公司章程"）的有关规定，制定本制度。 第二条 公司发生关联交易，应当保证关联交易的合法性、必要性、合理性和公允 性，保持公司的独立性，不得利用关联交易调节财务指标，损害公司利益。 第二章 关联人及关联交易认定 第三条 公司的关联人指具有以下情形之一的自然人、法人或其他组织： （一）直接或者间接控制公司的自然人、法人或其他组织； （二）直接或间接持有公司 5%以上股份的自然人； （三）公司董事、高级管理人员； （四）与上述关联自然人关系密切的家庭成员，包括配偶、年满 18 周岁的子女及 其配偶、父母及配偶的父母、兄弟姐妹及其配偶、配偶的兄弟姐妹、子女配偶的父母； （五）直接持有公司 5%以上股份的法人 ...

上海毕得医药科技股份有限公司 募集资金管理办法 第一章 总 则 第一条 为了规范上海毕得医药科技股份有限公司（以下简称"公司"）募 集资金的管理和运用，切实保护投资者的利益，依据《中华人民共和国公司法》、 《中华人民共和国证券法》、《上海证券交易所科创板股票上市规则》、《上市公 司募集资金监管规则》、《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等现行法律、法规及规范性文件及《上海毕得医药科技股份 有限公司章程》（以下简称"《公司章程》"）的规定，结合公司实际情况，制定 本办法。 第二条 本办法所称募集资金是指公司通过向不特定对象发行证券（包括首 次公开发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换 公司债券等）以及向特定对象发行证券募集的资金，但不包括公司实施股权激 励计划募集的资金。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于 主营业务，有利于增强公司竞争能力和创新能力。公司募集资金应当投资于科 技创新领域，促进新质生产力发展。 公司董事会应当持续关注募集资金存放、管理和使用情 ...